MedTrace Logo

Nebulized Hypertonic Saline for Bronchiolitis

NCT01460524 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2580

Last updated 2015-06-24

No results posted yet for this study

Summary

In randomized controlled trials, the use of nebulized hypertonic saline in acute bronchiolitis has been reported to improve respiratory distress scores, to reduce length of hospital stay and to show a trend towards lower hospitalization rates.

The investigators aim to verify by an observational study if the rate of hospital admission and the length of hospital stay of infants presenting to the emergency department (ED) with bronchiolitis decreases after the inclusion of 5.85% nebulized hypertonic saline in the treatment strategy of the ED and hospitalization wards.

The investigators will assess the evolution of hospital admission rates and the length of hospital stay in two hospitals that use 5.85% nebulized hypertonic saline for the treatment of bronchiolitis and in two hospital that do not use these nebulizations. If nebulized hypertonic saline is effective in this setting, then the hospitalization rates and length of stay should be lower during the year of hypertonic saline use compared to two previous years when this therapy was not used. These parameters would not be modified in centers that do not use hypertonic saline.

Conditions

  • Bronchiolitis

Sponsors & Collaborators

  • Hopital Universitaire Robert-Debre

    collaborator OTHER

  • Poissy-Saint Germain Hospital

    collaborator OTHER

  • Versailles Hospital

    collaborator OTHER

  • Hôpital Jean Verdier

    collaborator OTHER

  • Hôpital Armand Trousseau

    lead OTHER

Principal Investigators

  • Ricardo Carbajal, MD, PhD · Hôpital Armand Trousseau, Paris

Eligibility

Min Age
1 Day
Max Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01460524 on ClinicalTrials.gov